Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nataliya Fesenko
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
Ukrainian Engineering Pedagogics Academy
ORCID:
0009-0003-7187-0310
Observed ORCID:
0009-0003-7187-0310
OpenAlex ID:
A5079130033
FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review
2021
·
Abigail L. Koch
, Paz J. Vellanki
, et al.
·
Clinical Cancer Research
·
71
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer
2023
·
Sandra J. Casak
, M. Naomi Horiba
, et al.
·
Clinical Cancer Research
·
43
PDF
Education in the area of intellectual property as a condition of the stable state development
2017
·
Vadim Lunyachek
, Nataliya Ruban
, et al.
·
ScienceRise Pedagogical Education
·
13
PDF
Data from FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review
2023
·
Abigail L. Koch
, Paz J. Vellanki
, et al.
Data from FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review
2023
·
Abigail L. Koch
, Paz J. Vellanki
, et al.
Supplementary Table S1 from FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review
2023
·
Abigail L. Koch
, Paz J. Vellanki
, et al.
Show more works
View as search
Works count:
6
Citation count:
127
H-index:
3
I10-index:
3
Year
Topic
Type